 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 62
Date: December 12, 2024
CLL Topics was able to field a small team of reporters at the 2024 ASH Annual Meeting and Exposition in San Diego. Rainy skies kept us indoors attending the lectures and symposia - and a good thing, too, since there was a lot of material to cover. Click here to read our report on the ASH 2024 Highlights, including the latest news on prognostic indicators and how they influence therapy responses and survival, stem cell transplants, "Genasense", epigenetic therapy, interim results of a "vaccine" approach in CLL, etc., etc.
Of course, many of these topics are worthy of more in-depth analyses, keep an eye out for new articles on our website in the weeks to come.
Be well,
Chaya
_____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
